Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Emotion Regulation Program for Substance Use Disorders

7 de julho de 2026 atualizado por: Hae Kook Lee, The Catholic University of Korea

A Preliminary Study on the Effectiveness of a Psychosocial Treatment Program (Emotion Regulation Program) for Substance Use Disorders

This study examines whether a newly developed eight-session psychosocial treatment program, called the Emotion Regulation Program, can be delivered in real-world hospital settings to people receiving inpatient care for substance use disorders in Korea, and whether it shows early signs of benefit. The program combines motivational interviewing, acceptance and commitment therapy, and group activities, and is delivered twice a week over about four weeks (eight 50-minute sessions). About 20 adults will take part at two psychiatric hospitals.

Participants complete brief questionnaires and a short interview about their craving, motivation to change, difficulties in emotion regulation, self-compassion, depression, and drug use history before the program, immediately before and after each session, within one week after the program ends, and again at 1 month and 3 months after completion. After the program, some participants also join a small group discussion (focus group interview) to share their experience of the program.

Because this is a small, single-group preliminary (pilot) study without a comparison group, its primary purpose is to assess feasibility, that is, whether the program and the assessment approach work well enough, and to obtain preliminary effect and variability estimates to inform the design of a future large-scale randomized controlled trial.

Visão geral do estudo

Status

Ainda não está recrutando

Descrição detalhada

Background: Substance use among the Korean population has increased rapidly, with spread into adolescents and people in their twenties. Yet standardized, evidence-based psychosocial treatment programs and a corresponding clinician training and certification system are not well established in Korea. Evidence-based psychosocial interventions such as cognitive behavioral therapy, motivational interviewing, community reinforcement approaches, and 12-step facilitation are widely used as standard care in other countries, but comparable, locally validated programs are scarce in Korea. To address this gap, a Korean psychosocial treatment program (the Emotion Regulation Program) was developed, and this preliminary study evaluates its feasibility and preliminary effectiveness.

Objectives:

  1. Primary objective: to evaluate the real-world feasibility of delivering the Emotion Regulation Program to inpatients with substance use disorders.
  2. Secondary objective: to examine preliminary changes in craving (VAS-C), motivation to change (URICA-DO), difficulties in emotion regulation (DERS-SF), self-compassion (K-SCS), depression (PHQ-9), and drug use history and treatment service utilization, and to assess whether these measures are suitable for a future comparative trial.
  3. Tertiary objective: to explore participants' subjective experience and the acceptability of the program through a focus group interview, in order to refine the treatment manual and operational protocol for a future randomized controlled trial.

Design and setting: This is a single-arm, pre-post study with follow-up, without a control group. A total of 20 participants (10 per site) will be enrolled at two psychiatric hospitals that provide care to a large proportion of patients with drug use disorders in Korea (Incheon Chamsarang Hospital and Daegu Daedong Hospital). Study planning, rater training, informed consent storage, data management, and statistical analysis are coordinated centrally by the Catholic University of Korea. The two participating sites do not have their own IRB and are reviewed under the Uijeongbu St. Mary's Hospital IRB.

Intervention: The program consists of eight 50-minute group sessions delivered twice weekly over approximately four weeks. It integrates motivational interviewing, acceptance and commitment therapy, and group therapy, and draws on emotion-regulation and self-compassion skills. Session themes are: (1) understanding emotions and following the body's signals; (2) emotion regulation strategies I: grounding oneself through the senses when shaken; (3) emotion regulation strategies II: practicing choice rather than being swept away by emotion; (4) building a personal emotion-response scenario for moments of crisis; (5) facing the self-critical voice; (6) protecting oneself with warmth in difficult moments; (7) noticing and savoring positive moments; and (8) organizing a personal emotion-regulation routine to sustain going forward.

Assessment schedule: Baseline assessment occurs within one week before the program. Craving is assessed immediately before and after each session, along with session satisfaction and a therapist treatment-fidelity self-assessment. Post-intervention assessment occurs within one week after the program, followed by a focus group interview. Follow-up assessments are conducted at 1 month and 3 months after program completion.

Statistical analysis: Feasibility will be summarized using recruitment, retention, session attendance, and assessment completion rates. Change in continuous outcomes over time (pre, post, follow-up) will be analyzed using repeated-measures analysis of variance and linear mixed models; where covariate adjustment for repeated measures is needed, generalized estimating equations will be used. Analyses adjust for sociodemographic covariates and indication variables, or use stratified comparison. Missing data judged to be MCAR/MAR will be handled via maximum likelihood estimation within linear mixed models or multiple imputation, with sensitivity analyses. The main analysis is based on the full analysis set, with the per-protocol set as a supportive analysis. Qualitative focus group data will be transcribed and analyzed using thematic analysis (Braun & Clarke, 2006) by at least two independent coders.

Tipo de estudo

Intervencional

Inscrição (Estimado)

20

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

      • Daegu, Coréia do Sul
        • Daegu Daedong Hospital
        • Contato:
      • Incheon, Coréia do Sul
        • Incheon Chamsarang Hospital
        • Contato:
          • Younghoon Chon, MD, PhD
          • Número de telefone: +82-32-571-9111
          • E-mail: 8542231@daum.net

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion Criteria:

  • Adults aged 19 to 65 years who can understand the study purpose and procedures and provide written informed consent
  • Currently hospitalized (inpatient)
  • Able to communicate and complete questionnaires in Korean
  • Physically able to participate in program activities
  • Has completed detoxification treatment
  • Meets indication thresholds: DAST-10 score >= 2 and >= 2 DSM-5 criteria

Exclusion Criteria:

  • Cognitive impairment that precludes communication
  • Physical conditions that preclude program participation (e.g., musculoskeletal disorder, severe cardiopulmonary disease)
  • Acute psychotic symptoms or risk of self-harm or harm to others
  • At risk of disrupting group activities such that focus group participation is not feasible

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Emotion Regulation Program
All participants receive the Emotion Regulation Program, an eight-session group-based psychosocial treatment delivered twice weekly (50 minutes per session) over approximately four weeks. The program integrates motivational interviewing, acceptance and commitment therapy, and group therapy, and draws on emotion-regulation and self-compassion skills, covering emotional awareness, sensory grounding, choosing responses over reactions, crisis coping, self-compassion, savoring positive emotions, and a personalized emotion-regulation routine.
Eight 50-minute group sessions delivered twice weekly over approximately four weeks. Session 1: understanding emotions and following the body's signals. Session 2: emotion regulation strategies I (grounding oneself through the senses when shaken). Session 3: emotion regulation strategies II (practicing choice rather than being swept away by emotion). Session 4: building a personal emotion-response scenario for moments of crisis. Session 5: facing the self-critical voice. Session 6: protecting oneself with warmth in difficult moments. Session 7: noticing and savoring positive moments. Session 8: organizing a personal emotion-regulation routine to sustain going forward. Core techniques are motivational interviewing, acceptance and commitment therapy, and group therapy, incorporating emotion-regulation and self-compassion skills.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Feasibility: Program Completion (Retention) Rate
Prazo: From enrollment through the end of the 8-session intervention (approximately 4 weeks)
Proportion of enrolled participants who complete all eight sessions of the Emotion Regulation Program. Feasibility is further characterized by recruitment rate, session attendance, and assessment completion rates.
From enrollment through the end of the 8-session intervention (approximately 4 weeks)
Change in Craving (VAS-C)
Prazo: Immediately before and immediately after each of the 8 sessions (over approximately 4 weeks); baseline (within 1 week before the program); within 1 week post-intervention; 1 month and 3 months after completion
Craving measured by the Visual Analog Scale for Craving (VAS-C), ranging from 0 to 100 mm (0 = no craving, 100 = constant craving); higher scores indicate greater craving (worse outcome). Change from baseline is assessed at post-intervention and follow-up.
Immediately before and immediately after each of the 8 sessions (over approximately 4 weeks); baseline (within 1 week before the program); within 1 week post-intervention; 1 month and 3 months after completion

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change in Drug Use and Treatment Service Utilization
Prazo: Baseline, post-intervention (within 1 week), 1 month and 3 months after completion
Self-reported drug use history and treatment service utilization assessed via a structured 1:1 interview. Recall window is the past 30 days at most time points and the past 2 months at the 3-month follow-up.
Baseline, post-intervention (within 1 week), 1 month and 3 months after completion
Change in Motivation to Change (URICA-DO)
Prazo: Baseline (within 1 week before program), post-intervention (within 1 week after program), 1 month and 3 months after completion
Motivation to change (readiness) measured by the Korean version of the University of Rhode Island Change Assessment for Drug Offenders (URICA-DO), a 24-item scale rated from 1 (strongly disagree) to 5 (strongly agree) with four subscales (Precontemplation, Contemplation, Action, Maintenance). A Readiness to Change score is computed as the sum of the mean Contemplation, Action, and Maintenance subscale scores minus the mean Precontemplation subscale score (range -2 to 14); higher scores indicate greater readiness to change (better outcome).
Baseline (within 1 week before program), post-intervention (within 1 week after program), 1 month and 3 months after completion
Change in Difficulties in Emotion Regulation (DERS-SF)
Prazo: Baseline, post-intervention (within 1 week), 1 month and 3 months after completion
Difficulties in emotion regulation measured by the Difficulties in Emotion Regulation Scale-Short Form (DERS-SF), an 18-item scale rated from 1 to 5 (total range 18 to 90); higher scores indicate greater difficulties in emotion regulation (worse outcome).
Baseline, post-intervention (within 1 week), 1 month and 3 months after completion
Change in Self-Compassion (K-SCS)
Prazo: Baseline, post-intervention (within 1 week), 1 month and 3 months after completion
Self-compassion measured by the Korean version of the Self-Compassion Scale (K-SCS), a 26-item scale rated from 1 to 5; higher mean scores indicate greater self-compassion (better outcome).
Baseline, post-intervention (within 1 week), 1 month and 3 months after completion
Change in Depression (PHQ-9)
Prazo: Baseline, post-intervention (within 1 week), 1 month and 3 months after completion
Depressive symptoms measured by the Patient Health Questionnaire-9 (PHQ-9), a 9-item scale rated from 0 to 3 (total range 0 to 27); higher scores indicate more severe depression (worse outcome).
Baseline, post-intervention (within 1 week), 1 month and 3 months after completion
Program Acceptability (Focus Group Interview)
Prazo: Within 1 week after program completion
Acceptability and subjective experience of the program explored through a focus group interview using a semi-structured guide, analyzed by thematic analysis (Braun & Clarke, 2006).
Within 1 week after program completion

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Session Usefulness and Therapeutic Alliance
Prazo: Immediately after each of the 8 sessions (over approximately 4 weeks)
Participant-rated helpfulness of each session and therapeutic alliance on a visual analog scale from 0 to 10 (0 = not helpful at all, 10 = very helpful); higher scores indicate greater perceived usefulness and alliance (better outcome).
Immediately after each of the 8 sessions (over approximately 4 weeks)
Treatment Fidelity (Adherence Rate)
Prazo: Immediately after each of the 8 sessions
Therapist self-assessed treatment fidelity comprising common structural-fidelity items, session-specific core-practice items, and overall clinical-process fidelity items (yes/no), summarized as an adherence rate per session and per therapist.
Immediately after each of the 8 sessions

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Hae Kook Lee, The Catholic University of Korea

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de setembro de 2026

Conclusão Primária (Estimado)

1 de dezembro de 2026

Conclusão do estudo (Estimado)

1 de dezembro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

7 de julho de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

7 de julho de 2026

Primeira postagem (Real)

13 de julho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

13 de julho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

7 de julho de 2026

Última verificação

1 de julho de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

This is a small, single-group pilot study involving sensitive data from patients with substance use disorders. Given the limited sample size and re-identification risk, individual participant data will not be shared. Only de-identified, aggregated results will be reported.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever